Kelly Mitchell

7PUBLICATIONS
55CO-AUTHORS
Molecular targetsCancer cell biologyGenome structure and regulationCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Feb 02, 2023
WDR5 represents a therapeutically exploitable target for cancer stem cells in glioblastoma.

Kelly Mitchell, Samuel A Sprowls, Sonali Arora

|Sep 07, 2022
VRK1 Is a Synthetic-Lethal Target in VRK2-Deficient Glioblastoma.

Julie A Shields, Samuel R Meier, Madhavi Bandi

|Jan 25, 2022
Roadmap on plasticity and epigenetics in cancer.

Jasmine Foo, David Basanta, Russell C Rockne

|Mar 05, 2021
A circuitous route to GBM stem cell signalling.

Kelly Mitchell, Justin D Lathia

|Aug 11, 2020
A small-molecule allosteric inhibitor of BAX protects against doxorubicin-induced cardiomyopathy.

Dulguun Amgalan, Thomas P Garner, Ryan Pekson

|May 19, 2018
IL1RAP potentiates multiple oncogenic signaling pathways in AML.

Kelly Mitchell, Laura Barreyro, Tihomira I Todorova

Pageof 2

Frequent Collaborators

3 joint publications

Ulrich Steidl

2 joint publications

Swathi-Rao Narayanagari

2 joint publications

Justin D Lathia

1 joint publications

Luis A Carvajal